外周脊柱关节炎TNFi停药策略:甲氨蝶呤难以维持缓解
CRESPA 试验延伸阶段纳入 60 例外周脊柱关节炎(pSpA)患者,其中 25 例在戈利木单抗治疗 2 年后达到临床缓解并进入降阶梯策略,即停用戈利木单抗、改用甲氨蝶呤(MTX)单药。结果显示仅 4 例(16%)维持无生物制剂缓解,21 例(84%)因疾病复发或 MTX 相关不良事件重启戈利木单抗,重启后 12 周内全部恢复临床缓解。
要点
- pSpA 达缓解后以 MTX 替代戈利木单抗,84% 患者复发或出现 MTX 不良事件。
- 仅 16% 患者可在 MTX 单药下维持持续临床缓解。
- 重启戈利木单抗后 12 周内全部患者恢复临床缓解。
核心结论
- 早期 pSpA 患者经戈利木单抗治疗 2 年达临床缓解后,降阶梯为 MTX 单药导致高复发率,提示 MTX 在 pSpA 维持缓解中疗效总体较弱。
研究设计与样本
- CRESPA 试验(NCT01426815)2 年延伸阶段后开展的前瞻性降阶梯随访研究,原始 60 例 pSpA 患者中 25 例进入降阶梯策略。
主要发现
- 25 例进入降阶梯策略的患者中仅 4 例(16%)仍在 MTX 单药下维持持续缓解。
- 21 例(84%)重启戈利木单抗,原因包括疾病活动复发(n=19)与 MTX 相关不良事件(n=2)。
- 重启戈利木单抗后所有患者在 12 周内迅速恢复临床缓解。
关键数值与推荐
- 持续无生物制剂临床缓解率为 4/25(16%)。
- 重启戈利木单抗比例为 21/25(84%),其中疾病复发 19 例、MTX 相关不良事件 2 例。
- 重启戈利木单抗后 12 周内恢复临床缓解者为全部患者。
临床怎么用
- 对早期 pSpA 经 TNFi 治疗达持续缓解者,以 MTX 单药替代生物制剂的降阶梯策略失败率高,需谨慎选择并密切监测复发。
局限性
- 进入降阶梯策略的样本量较小(25 例),结果解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Treatment with golimumab monotherapy in early peripheral SpA (pSpA) results in higher rates of clinical remission compared with treatment in more longstanding disease. When reaching remission, treat-to-target recommendations suggest tapering of treatment. We therefore explored whether addition of MTX would permit discontinuation of golimumab in patients with pSpA in sustained clinical remission. METHODS: After a 2-year extension phase with golimumab treatment, patients with pSpA reaching clinical remission in the CRESPA trial were offered a tapering strategy leading to discontinuation of golimumab and replacement by MTX monotherapy. Patients were prospectively followed to assess the rate of sustained biologic-free clinical remission. In case of relapse of arthritis, enthesitis or dactylitis under MTX monotherapy, golimumab was restarted. RESULTS: Of the original 60 pSpA patients, 25 entered the step-down strategy. Currently, only 4 patients (16%) are still in sustained remission under MTX monotherapy. In 21 patients (84%), golimumab was reinstalled because of relapse of disease activity (n = 19) or development of adverse events related to MTX (n = 2). Restarting golimumab treatment promptly restored clinical remission in all patients within 12 weeks. CONCLUSION: In patients with early pSpA achieving clinical remission after 2 years of golimumab treatment, step-down therapy to monotherapy with MTX led to high rates of clinical relapse. This underscores the overall weak efficacy of MTX in maintaining clinical remission in pSpA. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01426815.
引用
- Carron P, De Craemer AS, Renson T, et al. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate. Rheumatology (Oxford). 2021. PMID: 33471112. doi:10.1093/rheumatology/keab056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。